文献速递系统性红斑狼疮

低剂量IL-2治疗系统性红斑狼疮的随机双盲安慰剂对照试验

Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Ann Rheum Dis · 2019-09-19

该随机双盲安慰剂对照试验纳入60例活动性SLE患者,评估低剂量IL-2联合标准治疗的安全性与疗效。12周主要终点SRI-4应答率未达统计学差异(55.17% vs 30.00%,p=0.052),但24周SRI-4应答率显著提高(65.52% vs 36.67%,p=0.027),狼疮肾炎完全缓解率亦显著优于安慰剂(53.85% vs 16.67%,p=0.036)。

要点

  • 12周主要终点SRI-4未达统计学显著(p=0.052),24周SRI-4应答显著优于安慰剂(p=0.027)。
  • 狼疮肾炎患者完全缓解率IL-2组53.85%,安慰剂组16.67%(p=0.036)。
  • IL-2组无严重感染,安慰剂组2例;IL-2可扩增Treg并增强NK细胞。

核心结论

  • 低剂量IL-2可能对活动性SLE有效且耐受性良好,但12周主要终点未达到。

研究设计与样本

  • 随机双盲安慰剂对照试验纳入60例活动性SLE患者,IL-2组30例、安慰剂组30例,均接受标准治疗12周并随访12周。

主要发现

  • 第12周SRI-4应答率IL-2组55.17%、安慰剂组30.00%(p=0.052),主要终点未达到。
  • 第24周SRI-4应答率IL-2组65.52%、安慰剂组36.67%(p=0.027)。
  • 狼疮肾炎完全缓解率IL-2组53.85%(7/13)、安慰剂组16.67%(2/12)(p=0.036)。
  • IL-2组未观察到严重感染,安慰剂组发生2例严重感染。
  • 低剂量IL-2扩增调节性T细胞,并可能通过增强自然杀伤细胞维持细胞免疫。

关键数值与推荐

  • 主要终点为第12周SRI-4应答率。
  • 次要终点包括其他临床应答、安全性和免疫细胞亚群动态。

临床怎么用

  • 低剂量IL-2可作为活动性SLE尤其是狼疮肾炎的潜在辅助治疗选择,但需注意12周主要终点未达统计学显著。
  • 治疗期间应监测免疫细胞亚群动态及感染事件。

局限性

  • 样本量较小(共60例),主要终点第12周未达到统计学显著。
  • 随访时间较短(24周),长期疗效与安全性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Open-labelled clinical trials suggested that low-dose IL-2 might be effective in treatment of systemic lupus erythematosus (SLE). A double-blind and placebo-controlled trial is required to formally evaluate the safety and efficacy of low-dose IL-2 therapy. METHODS: A randomised, double-blind and placebo-controlled clinical trial was designed to treat 60 patients with active SLE. These patients received either IL-2 (n=30) or placebo (n=30) with standard treatment for 12 weeks, and were followed up for additional 12 weeks. IL-2 at a dose of 1 million IU or placebo was administered subcutaneously every other day for 2 weeks and followed by a 2-week break as one treatment cycle. The primary endpoint was the SLE Responder Index-4 (SRI-4) at week 12. The secondary endpoints were other clinical responses, safety and dynamics of immune cell subsets. RESULTS: At week 12, the SRI-4 response rates were 55.17% and 30.00% for IL-2 and placebo, respectively (p=0.052). At week 24, the SRI-4 response rate of IL-2 group was 65.52%, compared with 36.67% of the placebo group (p=0.027). The primary endpoint was not met at week 12. Low-dose IL-2 treatment resulted in 53.85% (7/13) complete remission in patients with lupus nephritis, compared with 16.67% (2/12) in the placebo group (p=0.036). No serious infection was observed in the IL-2 group, but two in placebo group. Besides expansion of regulatory T cells, low-dose IL-2 may also sustain cellular immunity with enhanced natural killer cells. CONCLUSIONS: Low-dose IL-2 might be effective and tolerated in treatment of SLE. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registries (NCT02465580 and NCT02932137).

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. He J, Zhang R, Shao M, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2019. PMID: 31537547. doi:10.1136/annrheumdis-2019-215396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。